Olink Bioscience and Abnova signs co-marketing agreement to promote unique target-specific assays for cell signaling studies

20-Apr-2009 - Taiwan

Olink Bioscience and Abnova Corporation announced a co-development and co-marketing agreement. This collaboration will address the unmet need for high-performance assays for studies of protein phosphorylation and protein interactions by combining Abnova´s growing collection of antibodies with the Duolink® product line from Olink Bioscience. Hundreds of target-specific assays will be jointly marketed by the two companies, while sales of the proprietary products will be handled by the respective companies and their distributors.

Other news from the department business & finance

Most read news

More news from our other portals

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous